Zum Hauptinhalt springen
| Hans-Günter Meyer-Thompson | Covid-19

SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. 

SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. 

Grippin AJ, Marconi C, Copling S, Li N, Braun C, Woody C, Young E, Gupta P, Wang M, Wu A, Jeong SD, Soni D, Weidert F, Xie C, Goldenberg E, Kim A, Zhao C, DeVries A, Castillo P, Lohray R, Rooney MK, Schrank BR, Wang Y, Ma Y, Chang E, Kouzy R, Dyson K, Jafarnia J, Nariman N, Gladish G, New J, Argueta A, Amaya D, Thomas N, Doty A, Chen J, Copling N, Alatrash G, Simon J, Davies AB, Dennis W, Liang R, Lewis J, Wei X, Rinsurongkawong W, Vaporciyan AA, Johns A; D3CODE Team; Lee J, Lee JH, Sun R, Sharma P, Tran H, Zhang J, Gibbons DL, Wargo J, Kim BYS, Heymach JV, Mendez-Gomez HR, Jiang W, Sayour EJ, Lin SH. 

Nature. 2025 Nov;647(8089):488-497. doi: 10.1038/s41586-025-09655-y. Epub 2025 Oct 22. Erratum in: Nature. 2026 Nov 20. doi: 10.1038/s41586-026-10974-x. PMID: 41125896; PMCID: PMC12611756.

https://pmc.ncbi.nlm.nih.gov/articles/PMC12611756/